临床试验/JPRN-UMIN000033016

JPRN-UMIN000033016已完成1 期

Open label, efficacy and safety study of long-term 6-methylsulfinylhexyl Isothiocyanate(6-MSITC) administration to Duchenne muscular dystrophy - Long-term 6-MSITC administration to Duchenne muscular dystrophy

Kobe University0 个研究点目标入组 3 人开始时间: 2018年8月1日最近更新: 2023年10月17日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方: Kobe University
入组人数: 3

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 13years-old 至 ot applicable（—）
性别: Male

入选标准

未提供

排除标准

•DMD patient who has a severe complication DMD patient who joined other clinical trials within 6 months DMD patient who cannot swallow a capsule

研究者

发起方

Kobe University

相似试验

进行中（未招募）

A research study looking at long-term treatment with Mim8 in people with haemophilia A (FRONTIER 4)Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

KCT0008901ovo Nordisk29

A research study looking at long-term treatment withMim8 in people with haemophilia A

CTRI/2024/02/062683ovo Nordisk A/S

A research study looking at long-term treatment with Mim8 in people with haemophilia A(NN7769-4532)Participants with haemophilia A with or without FVIII inhibitors

JPRN-jRCT2041230047Esaki Risa425

进行中（未招募）

An Efficacy and 2-year Safety Study of Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial (inherited) Hypercholesterolaemia (high level of cholesterol in blood)

EUCTR2009-016492-29-Outside-EU/EEAAstraZeneca AB200

进行中（未招募）

An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial HypercholesterolaemiaMale and female children and adolescents (aged 6 to < 18 years) with FH* and at least 1 of the following criteria: 1. Fasting LDL-C>190 mg/dL (4.92 mmol/L) at baseline OR 2. Fasting LDL-C >160 mg/dL (4.10 mmol/L) at baseline in combination with evidence of other risk factors. *Familial hypercholesterolaemia is defined by a documented genetic defect in LDL receptor or Apo B or documented evidence of familial hypercholesterolaemia in a first-degree relative.

EUCTR2009-016492-29-BEAstraZeneca AB200